+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for Treating Hyperuricemia Market by Drug Class, Route Of Administration, Distribution Channel, Prescription Type - Global Forecast to 2030- Product Image
Drugs for Treating Hyperuricemia Market by Drug Class, Route Of Administration, Distribution Channel, Prescription Type - Global Forecast to 2030- Product Image
Sale

Drugs for Treating Hyperuricemia Market by Drug Class, Route Of Administration, Distribution Channel, Prescription Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6078774
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Navigating the Complexities of Hyperuricemia Management

Hyperuricemia, characterized by elevated serum uric acid levels, poses a significant and growing clinical challenge worldwide. As a precursor to gout and a contributor to renal and cardiovascular complications, it demands a nuanced understanding of its pathophysiology and treatment modalities. Recent epidemiological data reveal that the prevalence of hyperuricemia continues to rise, driven by lifestyle factors, genetic predispositions, and comorbid conditions such as obesity and metabolic syndrome.

This executive summary provides a concise yet thorough exploration of the current therapeutic armamentarium, highlighting the mechanisms of action, clinical applications, and safety profiles of available drug classes. By synthesizing data from peer-reviewed studies, regulatory filings, and expert interviews, it offers a foundational overview that informs subsequent sections on market dynamics, segmentation, and regional variations.

The discussion begins with the latest advances in recombinant uricase formulations, followed by an examination of uricosuric agents and xanthine oxidase inhibitors, each representing distinct strategies for addressing hyperuricemia. This introduction sets the stage for an in-depth analysis of shifts in treatment paradigms, tariff impacts, and segmentation insights, equipping stakeholders with the knowledge needed to navigate an increasingly complex landscape.

Key Shifts Reshaping the Treatment Paradigm

Over the past decade, the treatment landscape for hyperuricemia has undergone transformative shifts, driven by sustained innovation and evolving clinical guidelines. The introduction of novel recombinant uricase therapies has transformed the approach to refractory cases, offering rapid reduction of uric acid levels through enzymatic degradation. Concurrently, refinements in the development of uricosuric agents have improved tolerability and patient adherence, addressing previous safety concerns associated with renal excretion.

Advancements in xanthine oxidase inhibitors have expanded dosing flexibility and minimized drug-drug interactions, enabling broader application across patient profiles. Real-world evidence has underscored the importance of personalized medicine, prompting the investigation of biomarkers to tailor treatment selection and optimize outcomes. Regulatory agencies have also played a pivotal role by endorsing accelerated approval pathways, fostering faster access to breakthrough therapies.

These converging trends reflect a shift from one-size-fits-all regimens to targeted, patient-centric strategies that integrate genetic, metabolic, and lifestyle factors. As a result, clinicians and payers are increasingly focused on outcomes beyond serum urate reduction, emphasizing quality of life improvements and long-term safety. This section examines the key drivers behind these shifts and their implications for future therapeutic development.

Anticipating the Impact of US Tariff Adjustments 2025

In 2025, adjustments to United States tariffs on pharmaceutical imports are poised to exert a notable influence on the hyperuricemia treatment market. Changes in duty rates for active pharmaceutical ingredients and finished dosage forms will have ripple effects across manufacturing costs, supply chain logistics, and ultimately, pricing dynamics. Companies with vertically integrated operations may find opportunities to mitigate increased costs through domestic production enhancements, while those reliant on imports could face margin pressures.

Distribution channels are likely to adapt as inventory strategies evolve to pre-position critical stock and hedge against tariff-related uncertainties. Payers may respond by renegotiating reimbursement structures, influencing formulary placements and patient access. Meanwhile, manufacturers can leverage strategic partnerships with contract development and manufacturing organizations to optimize cost efficiencies and maintain competitive pricing.

Overall, the 2025 tariff landscape underscores the importance of supply chain resilience and proactive regulatory engagement. By anticipating these shifts, stakeholders can develop robust mitigation strategies that safeguard product availability and preserve market share amidst changing economic conditions.

Uncovering the Market Through Strategic Segmentation

Analyzing the market through the lens of drug class reveals three principal therapeutic categories. Recombinant uricase offers a biologic solution focused on enzymatic uric acid degradation, exemplified by the pegloticase formulation. Uricosuric agents enhance renal excretion and include lesinurad, which modulates urate transporter activity, alongside the long-established probenecid. Xanthine oxidase inhibitors target the synthesis pathway of uric acid, with allopurinol serving as a foundational therapy complemented by the more selective febuxostat.

When viewed by route of administration, the market divides between intravenous therapies, encompassing the infusion-based recombinant uricase, and oral formulations that characterize both uricosuric agents and xanthine oxidase inhibitors. This distinction influences patient convenience, adherence considerations, and distribution logistics.

The distribution channel perspective highlights the roles of hospital pharmacies, which manage inpatient and specialty clinic needs; online pharmacies, which cater to digital-savvy patients seeking home delivery; and retail pharmacies, which remain integral for outpatient prescriptions. Prescription type segmentation further differentiates branded products, often associated with premium pricing and specialty care settings, from generic formulations that drive accessibility and cost containment in broader patient populations.

By interweaving these dimensions, the segmentation framework illuminates nuanced adoption patterns and uncovers strategic opportunities for portfolio optimization and market penetration.

Regional Dynamics Driving Therapeutic Adoption

Regional analysis uncovers distinct trends influencing therapeutic uptake and competitive intensity. In the Americas, established healthcare infrastructures and high awareness of gout management have fostered rapid adoption of both novel biologics and next-generation small molecules. Payer negotiations and formulary competition are particularly rigorous, compelling manufacturers to demonstrate tangible value through real-world effectiveness and pharmacoeconomic evidence.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and varying reimbursement pathways present unique challenges. Markets in Western Europe exhibit a strong preference for oral xanthine oxidase inhibitors, while emerging markets within the region are beginning to adopt uricosuric agents and biologics as patient access programs gain traction.

The Asia-Pacific region demonstrates robust growth potential, driven by increasing healthcare expenditure and expanding access in both urban and rural settings. Preference for oral therapies remains dominant due to logistical considerations, yet pilot programs for infusion-based treatments signal an increasing openness to diversified modalities. Throughout these regions, demographic shifts and rising incidence of metabolic comorbidities continue to fuel demand for comprehensive hyperuricemia management strategies.

Competitive Landscape and Leading Innovators

An examination of leading companies reveals a dynamic environment characterized by innovation, strategic partnerships, and lifecycle management. Biologic specialists have prioritized enhancements to recombinant uricase platforms, exploring next-generation formulations with improved immunogenicity profiles. Major pharmaceutical firms continue to invest in combination therapy trials, assessing the synergistic effects of xanthine oxidase inhibitors with uricosuric agents to achieve more rapid and sustained serum urate control.

Generics manufacturers remain competitive in the xanthine oxidase inhibitor segment, leveraging cost-efficient production to capture volume-based markets. Specialty pharmaceutical companies are differentiating through patient support services and digital adherence tools, aiming to bolster long-term therapy persistence. Collaborations between established players and innovative biotech firms have accelerated the development of selective urate transporter inhibitors, representing the next frontier in targeted uricosuric mechanisms.

Collectively, these strategic moves reflect a commitment to addressing unmet clinical needs while optimizing commercial performance across diverse market segments. The interplay between brand equity, cost leadership, and patient-centric services defines the competitive contours of the hyperuricemia treatment landscape.

Actionable Strategies for Industry Advancement

To capitalize on emerging opportunities, industry leaders should align their R&D investments with precision medicine initiatives that identify patient subpopulations most likely to benefit from specific drug classes. Enhancing supply chain agility through dual-sourcing strategies and regional manufacturing hubs will mitigate tariff-related risks and improve responsiveness to demand fluctuations.

Collaborative engagements with healthcare systems and payers are essential for demonstrating real-world value and securing favorable formulary placements. Developing bundled care models that integrate pharmacotherapy with patient education and digital monitoring tools can differentiate offerings and drive adherence. In parallel, robust lifecycle management plans should explore label expansions for existing assets, including combination regimens and new delivery formats that cater to evolving patient preferences.

Finally, fostering open innovation partnerships with biotech startups and academic centers will accelerate the next wave of therapeutic breakthroughs. By embracing these actionable strategies, companies can navigate competitive pressures and deliver sustainable growth in the hyperuricemia market.

Rigorous Research Methodology Underpinning Insights

This research integrates primary and secondary methodologies to ensure comprehensive and reliable insights. Primary research involved in-depth interviews with key opinion leaders, including rheumatologists, nephrologists, and pharmacoeconomic experts, to capture clinical perspectives and unmet needs. Surveys administered to thought leaders across major markets provided additional context on adoption barriers and therapeutic preferences.

Secondary research encompassed analysis of peer-reviewed literature, regulatory approval documents, and industry white papers. Publicly available data sources, such as clinical trial registries and health authority databases, were systematically reviewed to validate drug profiles and pipeline developments. Market intelligence reports and financial filings supplied context on competitive strategies and investment trends.

Data triangulation techniques were applied to reconcile findings from diverse sources, ensuring consistency and accuracy. All insights underwent rigorous validation through cross-functional expert panels, reinforcing the credibility of conclusions and recommendations presented throughout this summary.

Synthesizing Insights for Informed Decision Making

Throughout this executive summary, the convergence of clinical innovation, market dynamics, and strategic imperatives has been highlighted to inform decision-makers. The interplay between evolving treatment paradigms, tariff considerations, and segmentation analysis provides a multidimensional view of the hyperuricemia landscape.

By integrating regional nuances and competitive intelligence, the findings equip stakeholders with a clear understanding of where to focus investments, partnerships, and patient engagement efforts. The actionable strategies delineated bridge the gap between insight and implementation, offering a roadmap for advancing therapeutic options while optimizing commercial outcomes.

Ultimately, this synthesis empowers leaders across the pharmaceutical value chain to make informed decisions that enhance patient care, drive sustainable growth, and maintain competitive advantage in a rapidly shifting environment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Class
    • Recombinant Uricase
      • Pegloticase
    • Uricosuric Agents
      • Lesinurad
      • Probenecid
    • Xanthine Oxidase Inhibitors
      • Allopurinol
      • Febuxostat
  • Route Of Administration
    • Intravenous
    • Oral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Prescription Type
    • Branded
    • Generic
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Horizon Therapeutics plc
  • Takeda Pharmaceutical Company Limited
  • Teijin Limited
  • Zambon S.p.A.
  • Menarini International Operations Luxembourg S.A.
  • Fuji Pharma Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs for Treating Hyperuricemia Market, by Drug Class
8.1. Introduction
8.2. Recombinant Uricase
8.2.1. Pegloticase
8.3. Uricosuric Agents
8.3.1. Lesinurad
8.3.2. Probenecid
8.4. Xanthine Oxidase Inhibitors
8.4.1. Allopurinol
8.4.2. Febuxostat
9. Drugs for Treating Hyperuricemia Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Drugs for Treating Hyperuricemia Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Drugs for Treating Hyperuricemia Market, by Prescription Type
11.1. Introduction
11.2. Branded
11.3. Generic
12. Americas Drugs for Treating Hyperuricemia Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Drugs for Treating Hyperuricemia Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Drugs for Treating Hyperuricemia Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Teva Pharmaceutical Industries Ltd.
15.3.2. Viatris Inc.
15.3.3. Novartis AG
15.3.4. AstraZeneca PLC
15.3.5. Horizon Therapeutics plc
15.3.6. Takeda Pharmaceutical Company Limited
15.3.7. Teijin Limited
15.3.8. Zambon S.p.A.
15.3.9. Menarini International Operations Luxembourg S.A.
15.3.10. Fuji Pharma Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DRUGS FOR TREATING HYPERURICEMIA MARKET MULTI-CURRENCY
FIGURE 2. DRUGS FOR TREATING HYPERURICEMIA MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS FOR TREATING HYPERURICEMIA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DRUGS FOR TREATING HYPERURICEMIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DRUGS FOR TREATING HYPERURICEMIA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS FOR TREATING HYPERURICEMIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PEGLOTICASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY LESINURAD, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PROBENECID, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ALLOPURINOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY FEBUXOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 45. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 46. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 47. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 48. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. CANADA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 54. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. MEXICO DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 72. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 87. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 89. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 90. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 91. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 93. GERMANY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 94. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 97. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 98. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. FRANCE DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 108. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 109. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 110. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 111. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 112. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ITALY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 115. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 117. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 118. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. SPAIN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 143. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 144. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 145. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 146. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 147. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. DENMARK DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 150. NETHERLANDS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 152. NETHERLANDS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 157. QATAR DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 158. QATAR DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 159. QATAR DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 160. QATAR DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. QATAR DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. QATAR DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. QATAR DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 165. FINLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 166. FINLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 167. FINLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 168. FINLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. FINLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. FINLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 180. NIGERIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 185. EGYPT DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 186. EGYPT DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 187. EGYPT DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 188. EGYPT DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 189. EGYPT DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. EGYPT DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. EGYPT DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 192. TURKEY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 193. TURKEY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 194. TURKEY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 195. TURKEY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 196. TURKEY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. TURKEY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. TURKEY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 199. ISRAEL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 206. NORWAY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. NORWAY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 208. NORWAY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 209. NORWAY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 210. NORWAY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NORWAY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. NORWAY DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 213. POLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. POLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 215. POLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 216. POLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 217. POLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. POLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. POLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 235. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 236. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 237. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 238. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 239. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 241. CHINA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 242. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 243. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 244. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 245. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 246. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. INDIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 249. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 251. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 252. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 253. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. JAPAN DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 270. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 271. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 272. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 277. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 279. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 280. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. THAILAND DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY RECOMBINANT URICASE, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY URICOSURIC AGENTS, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY XANTHINE OXIDASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES DRUGS FOR TREATING HYPERURICEMIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289.

Companies Mentioned

The companies profiled in this Drugs for Treating Hyperuricemia market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Horizon Therapeutics plc
  • Takeda Pharmaceutical Company Limited
  • Teijin Limited
  • Zambon S.p.A.
  • Menarini International Operations Luxembourg S.A.
  • Fuji Pharma Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Hyperuricemia - Pipeline Insight, 2025 - Product Image

Hyperuricemia - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Hyperuricemia Drugs Market Report 2025 - Product Image

Hyperuricemia Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Hyperuricemia Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 188 Pages
  • Global
From
Hyperuricemia - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Hyperuricemia - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Elitek or Fasturtec Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Elitek or Fasturtec Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.